107 related articles for article (PubMed ID: 27798863)
1. Substituted Tetrahydroisoquinolines as Microtubule-destabilizing Agents in Triple Negative Human Breast Cancer Cells.
Gangapuram M; Jean R; Mazzio E; Badisa R; Eyunni S; Goodman CB; Redda KK; Soliman KF
Anticancer Res; 2016 Oct; 36(10):5043-5052. PubMed ID: 27798863
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
Gangapuram M; Mazzio EA; Redda KK; Soliman KFA
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299315
[TBL] [Abstract][Full Text] [Related]
3. Quantitative phosphoproteomics reveals genistein as a modulator of cell cycle and DNA damage response pathways in triple-negative breast cancer cells.
Fang Y; Zhang Q; Wang X; Yang X; Wang X; Huang Z; Jiao Y; Wang J
Int J Oncol; 2016 Mar; 48(3):1016-28. PubMed ID: 26783066
[TBL] [Abstract][Full Text] [Related]
4. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 1-phenyl-1,2,3,4-dihydroisoquinoline compounds as tubulin polymerization inhibitors.
Zheng CH; Chen J; Liu J; Zhou XT; Liu N; Shi D; Huang JJ; Lv JG; Zhu J; Zhou YJ
Arch Pharm (Weinheim); 2012 Jun; 345(6):454-62. PubMed ID: 22415658
[TBL] [Abstract][Full Text] [Related]
6. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin.
ter Haar E; Hamel E; Balachandran R; Day BW
Anticancer Res; 1997; 17(3C):1861-9. PubMed ID: 9216636
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, antitubulin, and antiproliferative SAR of C3/C1-substituted tetrahydroisoquinolines.
Dohle W; Leese MP; Jourdan FL; Major MR; Bai R; Hamel E; Ferrandis E; Kasprzyk PG; Fiore A; Newman SP; Purohit A; Potter BV
ChemMedChem; 2014 Feb; 9(2):350-70. PubMed ID: 24436228
[TBL] [Abstract][Full Text] [Related]
8. Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC).
Chen Y; Tang Y; Mao B; Li W; Jin H; Zhang L; Liu Z
Molecules; 2018 Mar; 23(3):. PubMed ID: 29547591
[TBL] [Abstract][Full Text] [Related]
9. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of benzimidazole-oxindole conjugates as microtubule-targeting agents.
Kamal A; Nagaseshadri B; Nayak VL; Srinivasulu V; Sathish M; Kapure JS; Suresh Reddy C
Bioorg Chem; 2015 Dec; 63():72-84. PubMed ID: 26469740
[TBL] [Abstract][Full Text] [Related]
11. Anticancer mechanism of 7-α-hydroxyfrullanolide on microtubules and computational prediction of its target binding in triple-negative breast cancer cells.
Chimplee S; Smythe C; Tipmanee V; Sukrong S; Kanokwiroon K
PeerJ; 2022; 10():e13508. PubMed ID: 35651747
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers.
Kutty RV; Feng SS
Biomaterials; 2013 Dec; 34(38):10160-71. PubMed ID: 24090836
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells.
MacCarthy-Morrogh L; Townsend PA; Purohit A; Hejaz HAM ; Potter BVL ; Reed MJ; Packham G
Cancer Res; 2000 Oct; 60(19):5441-50. PubMed ID: 11034086
[TBL] [Abstract][Full Text] [Related]
15. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
16. Induction of microtubule hyper stabilization and robust G
Verma P; Manchukonda NK; Kantevari S; Lopus M
Fundam Clin Pharmacol; 2021 Dec; 35(6):955-967. PubMed ID: 33576046
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor activity of novel biisoquinoline derivatives against breast cancers.
Jaiswal AS; Hirsch-Weil D; Proulx ER; Hong S; Narayan S
Bioorg Med Chem Lett; 2014 Oct; 24(20):4850-3. PubMed ID: 25240616
[TBL] [Abstract][Full Text] [Related]
18. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Biological Evaluations of Ring Substituted Tetrahydroisoquinolines (THIQs) as Anti-Breast Cancer Agents.
Eyunni SV; Gangapuram M; Mochona B; Mateeva N; Redda KK
J Cancer Sci Ther; 2017; 9(7):528-540. PubMed ID: 29430288
[TBL] [Abstract][Full Text] [Related]
20. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
